Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data

ConclusionsThese findings suggest that blinatumomab provides substantial overall survival benefit to patients with (R/R) Ph( −) B-precursor ALL compared with salvage chemotherapy.FundingAmgen.Trial RegistrationClinicalTrials.gov identifier NCT01466179 and NCT02003612.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research